A major new study offers fresh hope for millions living with heart failure and obesity: anti-obesity jabs like Wegovy (semaglutide) and Mounjaro (tirzepatide) may cut the risk of hospitalization or premature death by nearly half.
Researchers from Mass General Brigham in Boston used health insurance data from over 90,000 U.S. adults diagnosed with heart failure with preserved ejection fraction (HFpEF), obesity, and type 2 diabetes.
They compared outcomes for people taking semaglutide or tirzepatide with those using sitagliptin – a common diabetes drug with no known heart-health benefits.
The results were striking: semaglutide users had a 42 percent lower risk of dying or being hospitalized, while tirzepatide users saw that risk drop by 58 percent compared to sitagliptin.
These findings were revealed at the European Society of Cardiology conference in Madrid and published in the Journal of the American Medical Association (JAMA) the same day.
HFpEFβwhere the heart can pump normally but doesnβt relax well – affects millions worldwide, and treatment options have been limited.
As Dr. Nils KrΓΌger, lead author, explained, βDespite the widespread morbidity and mortality burden of HFpEF, current treatment options are limited.β
He noted that semaglutide and tirzepatide are known for weight-loss and blood-sugar control but may offer βsubstantial benefitsβ by reducing serious heart failure outcomes.
Experts emphasize that these benefits go beyond weight loss. GLP-1 receptor agonists are gaining recognition for protecting the heart, kidneys, and possibly even the brain.
For example, semaglutide has also been shown to lower the risk of heart attack, stroke, or cardiovascular death by about 20 percent in a landmark trial of over 17,000 people.
Another real-world study, called STEER, found that Wegovy (semaglutide) may outperform tirzepatide in some cases.
Wegovy users had a 57 percent greater reduction in risk of heart attack, stroke, or death compared to tirzepatide users. Even when treatment gaps were factored in, Wegovy still showed a 29 percent lower risk.
Despite these encouraging results, experts urge caution. Because the study was observational based on claims data – it cannot prove direct cause and effect.
Randomized clinical trials are still needed to shape formal treatment guidelines.
The American College of Cardiology has already issued guidance encouraging clinicians to consider GLP-1 medications earlier for patients at cardiovascular risk, although randomized trials remain key.
This body of data paints a hopeful picture: GLP-1 weight-loss drugs like Wegovy and Mounjaro may soon be more than obesity tools – they could become powerful allies for heart patients too.
If future trials confirm these effects, treatment strategies may shift fundamentally.
To support your sleep quality and weight-loss journey, consider Sleep Lean Supplement, crafted with clean vitamins and plant extracts to help you sleep peacefully and recharge your body.
Better sleep can support metabolism and overall wellness, making it a helpful companion for anyone using heart-protective lifestyle strategies or medications.
Try Sleep Lean tonight for a gentle, restful experience that supports your goals.
